Opthalmic drug abuse and misuse in Jordan: An Observational Study from Community Pharmacies in Amman. by Al-Khalaileh, W et al.
 Al-Khalaileh, W, Abu Farha, R, Wazaify, M and van Hout, MC
 Opthalmic drug abuse and misuse in Jordan: An Observational Study from 
Community Pharmacies in Amman.
http://researchonline.ljmu.ac.uk/id/eprint/10124/
Article
LJMU has developed LJMU Research Online for users to access the research output of the 
University more effectively. Copyright © and Moral Rights for the papers on this site are retained by 
the individual authors and/or other copyright owners. Users may download and/or print one copy of 
any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. 
You may not engage in further distribution of the material or use it for any profit-making activities or 
any commercial gain.
The version presented here may differ from the published version or from the version of the record. 
Please see the repository URL above for details on accessing the published version and note that 
access may require a subscription. 
For more information please contact researchonline@ljmu.ac.uk
http://researchonline.ljmu.ac.uk/
Citation (please note it is advisable to refer to the publisher’s version if you 
intend to cite from this work) 
Al-Khalaileh, W, Abu Farha, R, Wazaify, M and van Hout, MC (2019) 
Opthalmic drug abuse and misuse in Jordan: An Observational Study from 
Community Pharmacies in Amman. Research in Social and Administrative 
Pharmacy. ISSN 1934-8150 
LJMU Research Online
Ophthalmic drug abuse: An observational study from community pharmacies in
Amman-Jordan
Waed Al-Khalaileh ⁠a, Rana Abu-Farha⁠b⁠, ⁠∗, Mayyada Wazaify ⁠a, Marie Claire Van Hout⁠c
a Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, The University of Jordan , Amman, Jordan
b Department of Clinical Pharmacy and Therpeutics, Faculty of Pharmacy, Applied Science Private University, Amman, Jordan
c Public Health Institute, Liverpool John Moore's University, United Kingdom
A R T I C L E I N F O
Keywords:
Abuse
Community pharmacy
Eye drops
Jordan
Misuse
Ophthalmic
A B S T R A C T
Background: There has been a trend in the past five years in Jordan for ophthalmic anticholinergic preparations
to be misused or abused. This is done mainly to experience mental altering effects such as mood changes, eupho-
ria or hallucinations. Such products are mostly obtained from community pharmacies without a prescription.
Objectives: This study aimed to observe the requests of ophthalmic preparations in community pharmacies in Am-
man, Jordan, and evaluating the most popular and frequently requested ophthalmic drops suspected of abuse.
Also, it aimed to describe the current methods that Jordanian community pharmacists use to manage such re-
quests.
Methods: A prospective cross-sectional observational study was conducted between November 2016 and January
2017at sixteen different community pharmacies in Amman. All ophthalmic products requested were observed
during this period.
Results: A total of 140 ophthalmic product requests for 130 customers were observed. Dry eye was the most
common complaint for which the customer requested the medication (n=30, 23.1%) and direct self-medication
(ie-requesting the product by name), was the most frequent method of purchase (n=63, 48.5%). In 19 cases
(14.6%), product requests were suspected to be for non-medical (ie-abuse) purposes. Most of the suspected cases
were for Pentolate⁠® (n=11, 57.9%), whereas 7 were for Prisoline⁠® (36.8%) and 1 for Naphcon-A⁠® (5.3%). The
majority of observed cases were for products requested without a prescription (n=16, 84.2%), and in 12 cases
out of which, sale was refused (63.2%).
Conclusion: More effort and enforcement of pharmacy regulation for safe dispensing is needed to reduce the abuse
of ophthalmic products. Educating pharmacists and ophthalmologists would help raise awareness and control the
type of drug abuse.
Introduction
Abuse of Over-the- Counter (OTC) and prescription medications is an
international issue.⁠1 OTC medications are those that can be bought from
pharmacies or other retail outlets without a prescription.⁠1 Although the
sale of OTC medications from community pharmacies may help individ-
uals to self-treat minor ailments, save time and effort of both patients
and physicians, some of these medicines can be misused or abused,
which subsequently may lead to other complications such as addiction.⁠2
It is important to differentiate between misuse and abuse terms when
talking about prescription or OTC drugs. ⁠3⁠,⁠4 In the literature, abuse is
defined as “any intentional, non-therapeutic use of a drug product or sub-
stance, even once, for the purpose of achieving a desirable psychological or
physiological effect”, while misuse is defined as “the use of the drug for le-
gitimate medical reason, yet, to use it wrongly either in terms of dosage or
duration”.⁠5 By definition, any medication can be misused, but only few
have the abuse potential, such as those with mind-altering or body-shap-
ing properties.⁠3 The most commonly reported prescription medications
to be abused worldwide are stimulants such as methylphenidate and
central nervous system (CNS) depressants such as sedatives (benzo-
diazepines) or some -anticonvulsants like clonazepam.⁠6 Moreover,
opioid-containing medications (that are sold without prescription in 
some countries like the UK), cough and cold remedies containing first 
generation antihistamines (e.g. diphenhydramine and chlorphen-
eramine), sympathomimetics (e.g. pseudoephedrine) and dextromethor-
phan are the top OTC products reported to be abused.⁠2
In Jordan, just like other countries in the region, with the excep-
tion of controlled drugs, the general public can buy almost any medica-
tion (both OTC and prescription) from the community pharmacy with-
out having a prescription.⁠7 This availability combined with relatively 
low price and accessibility of community pharmacies may contribute to 
the abuse of more and different kinds of OTC and prescription drugs.⁠7
A recently published scoping review described the abuse of topi-
cal ophthalmic anesthetics in 54 different publications world-wide (e.g. 
Brazil, USA, Italy, Turkey etc). It highlighted that such abuse had been 
reported in case series, case reports, and reviews and primarily had fo-
cused on toxicity and related complications of such product.⁠8
In Jordan, ophthalmic products that contain medications used to 
treat minor ailments that can be diagnosed in the community pharmacy 
(e.g. antihistamines used for allergic conjunctivitis like antazoline, or 
sympathomimetics for itchy red eye like naphazoline) can be obtained 
without a prescription. On the other hand, prescription-only-ophthalmic 
preparations contain medications that are used to treat internal eye con-
ditions and need to be diagnosed by a doctor (e.g. anticholinergic drugs 
used as mydriatic drugs (tropicamide, cyclopentolate) or beta blockers 
(timolol) or prostaglandins (latanoprost) used for glaucoma or conrti-
costeroids (efemoline) used for internal eye inflammation.
Ophthalmic anticholinergic preparations (e.g. tropicamide, cy-
clopentolate) are widely used to induce mydriasis and/or cycloplegia 
during eye examination.⁠9⁠,⁠10 The abuse of anticholinergic drugs, which 
has become well known especially in the 1980s, is related to their ef-
fect in causing euphoria and hallucination. The main reported reasons 
for abuse were: relaxing, getting high, induce pleasure, boosting energy, 
and eliminating depression.⁠9–11
Cycloplegic agents like cyclopentolate and tropicamide can enter 
the systemic circulation and reach to all systems easily by absorption 
through cornea and then the ocular drainage system.⁠9 Because of their 
dangerous systemic side effects, any small amount of these agents could 
lead to harm if misuse or abuse happens.⁠11 Several other types of oph-
thalmic drugs were mentioned in literature to be liable for abuse. These 
included topical anesthetic drugs (TADs),⁠12–15 topical ophthalmic decon-
gestants,⁠16 and topically applied Non-steroidal Anti-Inflammatory Drugs 
(NSAIDs).⁠12–17
Anecdotal reports in the past five y ears i n J ordan r evealed a n up-
ward trend of ophthalmic drugs abuse (i.e. - used to experience mental 
altering effects), with many products obtained from pharmacies without 
prescription.⁠18 To date, there has been only one study that investigated 
ophthalmic drug abuse from the perspective of 220 community phar-
macists in Jordan.⁠18 . This previous study involved questionnaires elic-
iting pharmacist self-report of suspected abuse of ophthalmic medica-
tions, which relied on pharmacists self-reporting of the suspected abuse 
of ophthalmic medications. A total of 178 pharmacists (80.9%) reported 
the abuse of some ophthalmic drugs, and they indicated that most of 
the ophthalmic products were obtained without a prescription (n = 136; 
61.8%). However, in this current study, we aimed to investigate this 
issue from a different angle by observing the requests of ophthalmic 
preparations in community pharmacies, evaluating the most popular 
and frequently requested ophthalmic drops suspected of abuse in com-
munity pharmacies and describing the main methods observed by the 
researcher and used by pharmacists to deal with suspected requests.
Methods
Study design, setting, subjects and data collection
This study adopted a prospective cross-sectional observational de-
sign. Data collection took place between November 2016 and January
2017 through 16 pharmacy in different regions of Amman, the capital of
Jordan. The selection of pharmacies was based on the convenience and
consenting to participate by the pharmacy manager of each community
pharmacy. Nevertheless, effort was made to try and approach pharma-
cies in diverse geographical locations in Amman.
All customers (all age groups/both genders) of the community phar-
macy asking for one or more eye drops/preparations during the observa-
tional period were recruited after consenting verbally to be interviewed
and no customer refusal for interviews was reported.
During the study period, two researchers had observed ophthalmic
drug requests for one week duration in each pharmacy. Some of the
pharmacies were observed during shift A work (from 9am to 3 pm)
while others were observed during shift B (from 3 pm to 12 am). In-
formed consent forms were obtained from all community pharmacists,
after describing that the aim of this study was to measure the oph-
thalmic drug abuse among customers in community pharmacies. To
minimize the social desirability effect (ie- Hawthorne effect), the re-
searchers noticed the interaction between customers and pharmacist
standing beside the pharmacist on the dispensing counter, wearing lab
coats to look like another pharmacist works in the same pharmacy. A
collaboration was made between the researchers and the main phar-
macist to detect the abuser among customers according to pharmacists’
prior knowledge with them.
Immediately following the observation and after the sale had been
made, customers were approached and asked to be interviewed by the
researcher. Customers were interviewed to obtain any additional infor-
mation thought to be important to the research, and the information
was written at the end of the data collection form.”
Data collection form
The data collection form in this study was anonymous and based on
a one validated and piloted by Wazaify and colleagues (2017). ⁠18 The
form had been designed to gather the following information without
mentioning any identifying information of customers or pharmacists:
A. Customer demographic data (age, gender and academic qualifica-
tion); obtained by interviewing the customers
B. Name of the ophthalmic product, quantity, indication and duration
of use; obtained by observing the customer-pharmacist interaction
C. Way of requesting the medication (on prescription, direct self-med-
ication (ie-asking for product by name), indirect self-medication
(ie-presenting symptoms and asking for pharmacist's advice); ob-
tained by observing the customers
D. Pharmacist's role in customer counseling (if any), obtained by ob-
serving the customer-pharmacist interaction. This section involved a
free-text to note down any information provided by the pharmacist
regarding the use, dose, the duration of use, administration of med-
ication, and how to manage side effect.
E. Pharmacist's reaction towards suspected cases of drug abuse, the
main signs that led the pharmacist and/or researchers to suspect
(e.g. the pattern and frequency of requests, pharmacists' familiarity
with customers and the large quantity requested), obtained by ob-
serving the customer-pharmacist interaction
F. General information about the participating pharmacy (e.g. Loca-
tion: whether in a mall, main-street or a side small street, Type:
chain or independent pharmacy), obtained by interviewing pharma
cists to see if these factors could affect the number of suspected cases
of abuse or the number of requests.
G. Pharmacist demographic data (age, gender, and experience), ob-
tained by interviewing pharmacists
Ethical considerations
This study was approved by the IRB of Jordanian Ministry of Health
(Reference number: MOH REC170001). In addition, verbal consents
were obtained from customers to be interviewed as well as from phar-
macists to use their demographic data. Written and signed consent form
was obtained from the pharmacy mangers to take part in this study.
Statistical analysis
All data were coded and entered into the Statistical Package for So-
cial Sciences (SPSS) database (version 23, IBM Corporation, Armonk,
NY, USA). Descriptive data were summarized as counts and percentages
for categorical variables and mean and SD for continuous variables.
Results
Baseline characteristics of study participating customers and recruited
pharmacists/pharmacies
Sixteen out of nineteen pharmacies approached agreed to take part
in the study, resulting in a response rate of 84.2%. The reason for re-
jection was that the responsible pharmacists were not interested in this
kind of research studies. Ten pharmacies (62.5%) were located in west
Amman and on a main road. Most of the pharmacists working in these
pharmacies were female (n=10, 62.5%) and one half (n=8, 50%)
were between 20 and 30 years old. Social demographic details of in-
volved pharmacists/pharmacies participating in the study are summa-
rized in Table 1.
During study period, a total of 130 different customers were inter-
viewed, most of whom were male (n=79, 60.8%) and between 21 and
40 years (n=81, 62.3%). More of the observations (n=111, 85.4%)
were recruited from independent pharmacies and working shift A (ie- 9
am-3pm; n=75, 57.7%). Demographic characteristics of the study par-
ticipating customers are presented in Table 2.
Table 1
Social demographic details of involved pharmacists/pharmacies participating in the study
(N=16).
Variable N %
Age
20–30 years 8 50%
31–40 years 5 31.3%
41–50 years 1 6.3%
>50 years 2 12.5%
Gender
Male 6 37.5%
Female 10 62.5%
Experience
<1 year 1 6.3%
1–5 years 4 25%
6–10 years 6 37.5%
>10 years 5 31.3%
Location of pharmacy
East Amman 6 37.5%
West Amman 10 62.5%
The road type
Main street 10 62.5%
Side/sub street 6 37.5%
Table 2
Demographic Characteristics of study participating customers during the observational 
part of the study (N= 130).
Variable N %
Age
<20 years 13 10%
21–40 years 81 62.3%
41–50 years 29 22.3%
50–60 years 5 3.8%
>60 years 2 1.5%
Gender
Male 79 60.8%
Female 51 39.2%
Site of recruitment
Chain Pharmacy 19 14.6%
Independent pharmacy 111 85.4%
Shift of recruitment
A (9am-3pm) 75 57.7%
B (3pm-12pm) 55 42.3%
*: No observations were made during working shift C due to lack of research assistants
covering this period.
Information regarding dispensed ophthalmic products
Various ocular complaints or reasons to request ophthalmic products
were noted by the observers during the study period. The top three com-
plaints were dry eyes (n=30, 23.1%), suspected eye infection (n=26,
20.0%) and eye redness (n=23, 17.7%). A summary of ocular com-
plaints and reasons to request ophthalmic products reported by cus-
tomers are presented in Fig. 1.
One hundred and forty (140) products were requested by the 130
customers during the study period. The average number of ophthalmic
products requested was 8.8 products/pharmacy/week. Direct self-med-
ication, by customer request without prescription, was the most fre-
quent way of requesting ophthalmic products (n=63, 48.5%), followed
by doctors’ prescription and pharmacists recommendations (n=48,
36.9%; n=19, 14.6%, respectively). The most commonly prescribed
products were lubricants (e.g. artificial tears, moisturizers; n=35,
25%), followed by decongestants & antihistamines (n=32, 22.9%).
Decongestants and antihistamines were the most commonly requested
products by direct self-medication, without prescription, (n=25/32). A
description of the ophthalmic products requested or prescribed during
the study is presented in (Table 3).
Ophthalmic products abuse evaluation among study observed customers
Over the study period, 19/130 observed cases (14.6%) were sus-
pected of drug abuse by either the researcher (n=2) or both; the phar-
macist and the researcher (n=17). These suspected cases involved 3
ophthalmic drugs of abuse; Pentolate⁠® (cyclopentotale) in 11 cases,
Prisoline⁠® (naphazoline and chlorpheniramine maleate) in 7 cases and
Naphcon-A⁠® (naphazoline and pheniramine maleate) in 1 case. Almost
all suspected abusers were male (n=18, 94.7%) and aged between 21
and 40 years (n=15, 78.9%). Most of them, (n=16, 84.2%) presented
no prescription and asked for the medication by name, whereas three of
them (15.8%) had brought prescription to get Pentolate⁠® eye drops.
Pharmacists’ responses to suspected drug abuse cases were diverse.
In most cases (47.4%, n=9) the pharmacist did not sell the requested
product and claimed that the product was not available. In six cases,
the pharmacist simply sold the drug of request (31.5%), in one case the
pharmacist sold a less quantity than requested (5.3%), In one case, the
pharmacist did not sell the requested product because of lack of pre-
scription (5.3%), and in two cases (10.5%) the pharmacist did not sell
the products because the drug was not actually available. The product
Fig. 1. Ocular Complaints presented by customers during the study period (N = 130). *Others: e.g. dust in the eye, glaucoma, foreign body entry, refuse to mention.
Table 3
Ophthalmic preparations dispensed (with/without prescription) during the study period.
Ophthalmic products Description method of request
N % Prescription
Indirect
self-
medication
Direct self-
medication
Lubricants 35 25% 13/35 3/35 19/35
Decongestants and
antihistamines
32 22.9% 2/32 5/32 25/32
Antibiotics 23 16.4% 17/23 4/23 2/23
Antibiotic and
steroid
combination
14 10% 7/14 5/14 2/14
Anticholinergic
agents
14 10% 6/14 0/14 8/14
Steroids 11 7.9% 8/11 1/11 2/11
Glaucoma
medications
7 5% 2/7 0/7 5/7
NSAID 3 2.1% 0/3 1/3 2/3
Other⁠a 1 0.7% 1/1 0/1 0/1
a Witch hazel (Eye Bright) Eye drop.
had been sold in 7 out of the 19 suspected cases of abuse (36.8%) and
not sold in remainder (63.2%). The quantity of ophthalmic products of
abuse requested by one customer ranged between 1 and 5 (mean=1.7).
Detailed information about the 19 suspected cases are presented in
Table 4.
The reasons for suspected abuse of ophthalmic products were based
on customers’ reactions and answers during the interview (e.g. anxi-
ety, confusion, hesitation, lying, and requesting another drug of abuse)
(n=9, 47.4%), incompatibility among the symptoms mentioned by the
customers and the requested eye drop (n=4, 21.1%), and based on
prior pharmacist experience with the customer (n=6, 31.6%).
Discussion
The study is first of its kind in Jordan to observe ophthalmic drug
abuse in community pharmacy, and has illustrated the complexities of
suspected abuse of prescription and nonprescription ophthalmic prepa-
rations in community pharmacy settings in Amman. In addition, the
study reports the ophthalmic products most frequently suspected of
abuse and highlighted the methods used by Jordanian pharmacists to
manage such requests.
In this study, independent pharmacies represented the majority of
our sample. This is because the majority of community pharmacies in
Jordan are independent rather than chain. According to the Jordan
Pharmaceutical Association (JPA), there are a total of 3214 community
pharmacies in Jordan. The number of chains is 56 and estimated to have
200 branches around Jordan. All the rest are independent pharmacies.
Few studies described the problem of ophthalmic products misuse
in the literature, either from the pharmacy staff perspective⁠4⁠,⁠7 or by
measuring the general public's attitudes towards these medications.⁠18–21
Dry eye and lubricants were the most reported complaint and dispensed
ophthalmic products, respectively. This may be attributed to the time in
which the study was conducted, and the transition from autumn to win-
ter. Although ophthalmic lubricants are considered safe drugs; corneal
epithelial toxicity could occur as a result of using multi dosing products
for long durations. This is attributable to the preservatives present, es-
pecially benzalkonium chloride.⁠22
Several serious medical consequences like blindness have been re-
ported in the literature due to OTC ophthalmic drug misuse.⁠20 In the
present study, decongestants and antihistamines were the most fre-
quently requested products by direct self-medication method. Soparker
and workers (1997), in their study described the different patterns of
conjunctivitis triggered by misusing ophthalmic decongestants. Follicu-
lar conjunctivitis, eczematoid blepharoconjunctivitis, and conjunctival
hyperemia were observed with long-term usage of ophthalmic decon-
gestants, regardless of the purpose of use (misuse or abuse). ⁠16 It is con-
cerning that in our study more than half of lubricant requests were re-
quested through direct self-medication. Thus, it is important to educate
customers about such consequences and the responsibility of customers
education situates within both ophthalmologists and community phar-
macist professional practice.⁠23
During the observation period, eleven customers were suspected to
abuse cyclopentolate eye drops while eight customers were suspected of
abusing naphzoline under two brand names (seven cases for Prisoline⁠®,
and one case for Naphcon-A⁠®). All of the reported products at this sec-
tion in the study are classified by the Jordan Food and Drug Administra-
tion (JFDA) as OTC products except for pentolate⁠® (cyclopentolate). The
abuse of Pentolate⁠®, Prisoline⁠®, and Naphcon-A⁠®, had been reported
previously in Jordan from pharmacists’ perspective using cross-sectional
survey method.⁠4⁠,⁠18 However, this trend has not surfaced in community
pharmacy until 5 years ago⁠7 as cheap and legal alternative to other con-
trolled or illicit drugs.⁠24
Table 4
Details of the observed cases suspected of ophthalmic drug abuse during the study (N= 19).
#
Chain/
Independent
Pharmacy
Participant
gender/
age
Eye drop/
Quantity ⁠a Request method
Used
before
Compliant
by
customer
Customer
Familiarity
Pharmacist
response/
reason, if not
sold Suspicious reasons
1 Independent Male
21–40
years
Prisoline⁠®
1
By customer
without
prescription
Yes Redness Non
Familiar
Sold the drug No redness was appearing. In
addition, the customer asked for
Lyrica ⁠®
2 Independent Male
21–40
years
Prisoline⁠®
1
By customer
without
prescription
yes Redness
and
Itching
(Allergy),
for his
mother
Non
Familiar
Refusing to sell
under the
pretext of lack
of medicine
Anxiety and confusion apparent
during the conversation
3 Chain Male
21–40
years
Prisoline⁠®
1
By customer
without
prescription
Yes Refuse to
mention
Familiar Refusing to sell
under the
pretext of lack
of medicine
The way of asking, appearance
and he refused to talk with the
observer pharmacist
4 Chain Male
21–40
years
Pentolate⁠®
1
By customer
without
prescription
Yes To induce
mydriasis
Familiar Refusing to sell
under the
pretext of lack
of medicine
The pharmacist told that this
customer always come to the
pharmacy and ask for
pentolate⁠®
5 Independent Male
21–40
years
Pentolate⁠®
1
By customer
without
prescription
Yes To induce
mydriasis
before
surgery
Non
familiar
The drug is not
existing
The way of asking, appearance,
no prescription and when we
asked him about the surgery, he
confused and didn't answer
6 Independent Male
21–40
years
Pentolate⁠®
1
By customer
without
prescription
Yes Refused
to
mention
Non
familiar
Refusing to sell
under the
pretext of the
absence of a
prescription
The pharmacist told that this
customer came before and asked
for pentolate ⁠®
7 Independent Male
21–40
years
Prisoline⁠®
2
By customer
without
prescription
Yes Redness Non
familiar
Sold the drug The customer came with his
friend and ask for two bottles.
8 Independent Male
21–40
years
Pentolate⁠®
1
By customer
without
prescription
Yes Dry eye
and
redness
Familiar Refusing to sell
under the
pretext of lack
of medicine
Because pentolate ⁠® eye drop not
used for redness or for dry eye
9 Independent Male
21–40
years
Prisoline⁠®
2
By customer
without
prescription
Yes Burning
sensation
Familiar Sold the drug The pharmacist told that this
customer always asked for this
eye drop in large quantities.
10 Independent Male
21–40
years
Pentolate⁠®
1
By customer
without
prescription
Yes Dry eye
and
redness
Non
familiar
Sold the drug Because pentolate ⁠® eye drop not
use for redness or for dry eye
11 Independent Male
21–40
years
Prisoline⁠®
2
By customer
without
prescription
Yes Refused
to
mention
Non
familiar
Refusing to sell
under the
pretext of lack
of medicine
Appearance and his way of
asking, requesting two bottles.
In addition, he mentioned all
the alternatives
12 Independent Male
21–40
years
Pentolate ⁠®
4
By customer
without
prescription
Yes To induce
mydriasis
before
surgery
Non
familiar
Refusing to sell
under the
pretext of lack
of medicine
The customer asked for all the
quantity present in the
pharmacy which was 4
13 Independent Male
41–50
years
Naphcon-A⁠®
5
By customer
without
prescription
Yes Redness Non
familiar
Refusing to sell
under the
pretext of lack
of medicine
He was insisting to buy the
drug, and left his number to call
him when the drug became
available
14 Independent Male
21–40
years
Pentolate⁠®
1
By customer
without
prescription
Yes Redness
(Allergy)
Non
familiar
Sold the drug Pentolate⁠® eye drop not used
for allergy
15 Chain Male
21–40
years
Pentolate⁠®
1
By prescription
written by
general doctor
Yes To induce
mydriasis
before
surgery
Familiar The drug is not
existing
The pharmacist told that this
customer came every two days
with a prescription
16 Independent Female
41–50
years
Pentolate⁠®
2
By prescription
written by
general doctor
Yes To induce
mydriasis
before
surgery
Familiar Refusing to sell
under the
pretext of lack
of medicine
The pharmacist told that this
woman came frequently with
different prescriptions written
by ophthalmologists or general
doctors
17 Independent Male
41–50
years
Pentolate⁠®
2
By prescription
written by
ophthalmologist
Yes To induce
mydriasis
Familiar Refusing to sell
under the
pretext of lack
of medicine
The pharmacist told that this
customer was frequently coming
to take this eye drop and when
the pharmacist told him that
there must be a prescription, he
brought a prescription.
Table 4 (Continued)
#
Chain/
Independent
Pharmacy
Participant
gender/
age
Eye drop/
Quantity ⁠a
Request
method
Used
before
Compliant
by
customer
Customer
Familiarity
Pharmacist
response/
reason, if not
sold Suspicious reasons
18 Independent Male
41–50
Prisoloine⁠®
3
By customer
without
prescription
Yes Redness
and
Itching
Familiar Sold the drug,
but in less
quantity, only
one bottle.
Appearance and his way of
asking. In addition, he requested
three bottles.
19 Independent Male
20–40
Pentolate⁠®
1
By customer
without
prescription
Yes He told
that he is
sick and
need this
drug
Familiar Sold the drug The Customer didn't clarify his
disease and why he wants the
medication
a Number of packages.
In terms of these observed cases of suspected abuse of ophthalmic
products in Amman, it was notable that the majority occurred in inde-
pendent pharmacies as opposed to chain pharmacies. We speculate that
this trend could be due to the lack of uniform sales protocols when deal-
ing with suspected abuse of medicinal products in independent phar-
macies, as opposed to network protocols often present for employees in
chain pharmacies. On the other hand, in independent pharmacies, retail
pressures to generate income could influence decisions to dispense, de-
spite suspected abuse.⁠24
Study limitations
The main limitations of this study were:
1. The study was conducted in a single city at Amman, capital of Jor-
dan, and hence the results might not be generalizable to other cities
in Jordan but on the other hand, every effort had been made to cover
different regions of Amman to ensure representativeness.
2. The obtained sample size was in general small. However, the sample
was higher than the minimum target sample calculated by the statis-
tician (n=120).
3. As the study researchers were females, no observations were made
during working shift C, which may have affected the results. How-
ever, the researchers have fully covered both shifts, A and B in all
recruited pharmacies.
4. The observation period, one week for each pharmacy may have not
been enough and may have affected the results.
5. Many ophthalmic products as Pentolate⁠® and Prisoline⁠® were not
available in the pharmacies during the observation which could un-
derestimate the number of cases suspected of abuse, who could have
obtained the products from those pharmacies.
6. The human error during reporting and observing cases cannot be
ignored, such as inter-rater reliability between the two researchers
and subjectivity in judgment. However, every effort was made dur-
ing training of the researchers to maximize consistency (as described
in Method section) and minimize this kind of error.
7. Although every effort had been made to assure pharmacists of the
confidentiality and anonymity of the study and that it was done
solely for research purposes by the academic team, the Hawthorne
effect could not be totally negated, as some pharmacists may have
behaved differently in the presence of the researchers, which may
have affected the results of the study.
Future work
This study provides a baseline data to build on in future studies;
long-term study targeting different cites in Jordan with larger sample
size to obtain more generalizable data. In addition, a qualitative study
using in-depth interviews with customers suspected of drug absue is
also recommended to better understand the main factors behind oph-
thalmic drug abuse.
Conclusion
Observations in this study showed that 1 in every 6 requests of
opthalmic products in community pharmacies in Amman is suspected of
abuse where the product had been sold in almost 40% of suspected cases
of abuse. The most commonly products suspected of abuse are anti-
cholinergics and sympathomimetics. The study underscores the need for
regulatory efforts to manage specific ophthalmic products (Pentolate⁠®,
Prisoline⁠® and Naphcon-A⁠®) abuse, through a more proactive role of the
pharmacist rather than just refusing sale. Create a registry of those using
the products and that can help pharmacists better flag excessive users of
a particular product can be one suggestion. Also, Jordan Pharmaceutical
Association and JFDA should develop best practices in the community
pharmacy's for detection and management of all types of prescription
and nonprescription drug abuse including ophthalmic medications.
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